Chr. Hansen expands strain library
Global bioscience company Chr. Hansen has expanded its strain library of potential microbiome modulating strains.
“As part of its Nature’s No. 1 strategy, Chr. Hansen has a strategic focus on the human microbiome. We can announce that we are making significant progress in this area. From over 1000 recently screened strains from the human microbiome, we have identified a subset of 100 that can be developed for a broad array of health indications associated with gastrointestinal, immune and metabolic health,” said Johan van Hylckama Vlieg, VP Microbiome and Human Health Innovation.
These strains will be used for Chr. Hansen’s internal innovation efforts and made available to external partners and customers looking to accelerate development of next-generation probiotics.
Developing microbiome strains as next-generation probiotics for pharma, food, supplement, infant and pharma applications presents unique challenges. Many of the relevant species have no history of commercialisation. They were until recently described as difficult to cultivate and require radically new techniques for cultivation and production.
The strains in the Chr. Hansen strain collection have passed rigorous safety assessments and are amendable for production and formulation into products in an industrial setting.
“Our safety assessment includes screening for absence of antibiotic resistance and virulence factors. We also looked for their ability to grow in industrial media and sensitivity to oxygen. And we also screened for the ability of strains to impact the immune system,” explained Gemma Henderson, Senior Scientist.
The work has been carried out in partnership between Chr. Hansen and three academic institutes — Gut Health, The Rowett Institute, University of Aberdeen; Host-Microbe Interactomics, Wageningen University and Research; and Medical Microbiology, UMCG, University of Groningen.
“Now we have a shortlisted selection of strains that we believe will be of major interest to innovators in the microbiome space, who are looking to develop the next generation of probiotics and live biotherapeutics. It is our goal to help our customers and partners move these new documented strains from the lab to the clinic,” said Henderson.
A subpopulation of immune cells that normally fend off pathogens can turn against the host during...
Clinical trials accounted for roughly $1.1 billion in gross expenditure in 2015, and the annual...
Molecular diagnostics company Genetic Signatures has received Australian and European regulatory...